Zobrazeno 1 - 10
of 148
pro vyhledávání: '"Xiaoxue Zhu"'
Publikováno v:
Journal of Theoretical and Applied Electronic Commerce Research, Vol 18, Iss 4, Pp 1799-1819 (2023)
The meal delivery routing problem faced by the e-commerce platform is challenging. In order to reduce the logistics cost and meet the needs of customers, a multi-objective meal delivery routing problem is studied under the shared logistics services m
Externí odkaz:
https://doaj.org/article/0e6c02a184504c5e8ac3e94db3c3f58d
Autor:
Yue Hu, Haijun Li, Hong Zhang, Xiaoxin Chen, Jinjun Chen, Zhongyuan Xu, Hong You, Ruihua Dong, Yun Peng, Jing Li, Xiaojiao Li, Dandan Wu, Lei Zhang, Di Cao, He Jin, Dongdong Qiu, Aruhan Yang, Jinfeng Lou, Xiaoxue Zhu, Junqi Niu, Yanhua Ding
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-11 (2023)
Abstract Non-alcoholic fatty liver disease is a growing health burden with limited treatment options worldwide. Herein we report a randomized, double-blind, placebo-controlled, multiple-dose trial of a first-in-class pan-phosphodiesterase inhibitor Z
Externí odkaz:
https://doaj.org/article/0f26d90508ff44b7842b58475fd6e548
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 12 (2024)
Introduction: Electromyography (EMG) normalization often relies on maximum voluntary isometric contraction (MVIC), which may not be suitable for knee osteoarthritis (KOA) patients due to difficulties in generating maximum joint torques caused by pain
Externí odkaz:
https://doaj.org/article/9941b5e84b2f44fca202f7e87a491714
Autor:
Jia Xu, Hong Zhang, Hong Chen, Xiaoxue Zhu, Haiyan Jia, Zhongnan Xu, Dandan Huo, Cuiyun Li, Yanhua Ding
Publikováno v:
Annals of Medicine, Vol 55, Iss 2 (2023)
AbstractBackground: TQA3526 is a novel farnesoid X receptor agonist developed to treat non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC). This study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharma
Externí odkaz:
https://doaj.org/article/21c9bbece98d4361bc32077cb24b1fdd
Autor:
Cuiyun Li, Min Wu, Hong Zhang, Xiaoxue Zhu, Li Fu, Shuo Wang, Mingming Lu, Dafang Zhong, Yanhua Ding
Publikováno v:
Annals of Medicine, Vol 55, Iss 2 (2023)
AbstractBackground Forsythin, an active compound from Forsythiae Fructus, has the potential to treat the common cold and influenza through its antipyretic-analgesic, anti-inflammatory and antiviral effects. The safety, tolerability and pharmacokineti
Externí odkaz:
https://doaj.org/article/e01418cc159b4eae9a69954eff4379ed
Autor:
Haiyan Jia, Jiajia Mai, Min Wu, Hong Chen, Xiaojiao Li, Cuiyun Li, Jingrui Liu, Chengjiao Liu, Yue Hu, Xiaoxue Zhu, Xiuhong Jiang, Bo Hua, Tian Xia, Gang Liu, Aiyun Deng, Bo Liang, Ruoling Guo, Hui Lu, Zhe Wang, Huanming Chen, Zhijun Zhang, Hong Zhang, Junqi Niu, Yanhua Ding
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-11 (2023)
Abstract Background Hepatitis B virus (HBV) core protein-targeting antivirals (CpTAs) are promising therapeutic agents for treating chronic hepatitis B (CHB). In this study, the antiviral activity, pharmacokinetics (PK), and tolerability of ZM-H1505R
Externí odkaz:
https://doaj.org/article/02bce6f28a1643cd90afd9d651ebfed5
Autor:
Yue Hu, Xiaojiao Li, Jingrui Liu, Hong Chen, Wenbo Zheng, Hong Zhang, Min Wu, Cuiyun Li, Xiaoxue Zhu, Jinfeng Lou, Pangke Yan, Nan Wu, Xiao Liu, Shiping Ma, Xu Wang, Yanhua Ding, Chengluan Xuan
Publikováno v:
Annals of Medicine, Vol 54, Iss 1, Pp 2758-2769 (2022)
Background The primary objective of this study was to investigate if hepatic impairment alters the safety, pharmacokinetics, and pharmacodynamics of HSK3486.Research design and methods This was a clinical trial of HSK3486 in subjects with normal hepa
Externí odkaz:
https://doaj.org/article/47b2fb3c1cea48198dbee99496937eed
Autor:
Mingtong Xu, Xiaoxue Zhu, Junyan Wu, Yuling Zhang, Dong Zhao, Xuhong Wang, Yanhua Ding, Yu Cao, Chengqian Li, Wei Hu, Jianlong Sheng, Zhu Luo, Zeqi Zheng, Jinfang Hu, Jianying Liu, Xiaoyang Zhou, Aizong Shen, Xiaomei Ding, Yongdong Zhang, Yonggang Zhao, Yijing Li, Sheng Zhong, Shimin An, Jianjun Zou, Li Yan
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-13 (2022)
Abstract Background Recaticimab (SHR-1209, a humanized monoclonal antibody against PCSK9) showed robust LDL-C reduction in healthy volunteers. This study aimed to further assess the efficacy and safety of recaticimab in patients with hypercholesterol
Externí odkaz:
https://doaj.org/article/eddd24c943b4457a9f6b80de4dde2c34
Autor:
Hong Zhang, Lei Gao, Jinfeng Lou, Min Wu, Hong Chen, Lizhi Yang, Jingrui Liu, Xiaoxue Zhu, Xiaojiao Li, Cuiyun Li, Meng Wang, Chengjiao Liu, Weibo Guo, Yuan Wang, Zhongqiang Gao, Lei Han, Daidi Wang, Weili Jin, Yanhua Ding
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Objective: Hepenofovir, a novel hepatic targeting prodrug of tenofovir, has been developed for the treatment of chronic hepatitis B (CHB). This is a first-in-human study to evaluate the pharmacokinetics (PK) and tolerability of single and multiple es
Externí odkaz:
https://doaj.org/article/bdc071679ee3447090eceb5b35747935
Autor:
Hong Zhang, Xiaojiao Li, Jingrui Liu, Cuiyun Li, Min Wu, Xiaoxue Zhu, Jixuan Sun, Min Fang, Yanhua Ding
Publikováno v:
Annals of Medicine, Vol 53, Iss 1, Pp 375-383 (2021)
AbstractPurpose QX003S is a biosimilar candidate for the reference tocilizumab, Actemra®. We investigated the tolerance, variability, and pharmacokinetics (PK) of QX003S biosimilar in healthy Chinese male subjects.Design A randomised, double-blind,
Externí odkaz:
https://doaj.org/article/d226eed6d169454286b7c306314fa8f9